A Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered DF-003 Following Single (Part 1) and Multiple (Part 2) Ascending Doses in Healthy Subjects
Latest Information Update: 02 Jun 2025
At a glance
- Drugs DF 003 (Primary)
- Indications Cardiovascular disorders; Renal failure; Retinal disorders
- Focus Adverse reactions; First in man
- Sponsors Drug Farm
Most Recent Events
- 29 May 2025 According to a Drug Farm media release, company presented result data from this study at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) meeting in Washington.
- 29 May 2025 Results (n=48) published in the Media Release.
- 30 Apr 2024 Status changed from recruiting to active, no longer recruiting.